ESBL  ||| S:0 E:5 ||| NNP
and  ||| S:5 E:9 ||| CC
carbapenemases  ||| S:9 E:24 ||| NN
in  ||| S:24 E:27 ||| IN
Enterobacteriaceae  ||| S:27 E:46 ||| NNP
Carbapenemase-producing  ||| S:46 E:70 ||| JJ
enterobacteria  ||| S:70 E:85 ||| NNS
( ||| S:85 E:86 ||| -LRB-
CPE ||| S:86 E:89 ||| NNP
)  ||| S:89 E:91 ||| -RRB-
spread  ||| S:91 E:98 ||| VBD
all  ||| S:98 E:102 ||| DT
over  ||| S:102 E:107 ||| IN
the  ||| S:107 E:111 ||| DT
world  ||| S:111 E:117 ||| NN
during  ||| S:117 E:124 ||| IN
the  ||| S:124 E:128 ||| DT
last  ||| S:128 E:133 ||| JJ
years ||| S:133 E:138 ||| NNS
,  ||| S:138 E:140 ||| ,
causing  ||| S:140 E:148 ||| VBG
serious  ||| S:148 E:156 ||| JJ
infections  ||| S:156 E:167 ||| NNS
with  ||| S:167 E:172 ||| IN
increasing  ||| S:172 E:183 ||| VBG
frequency ||| S:183 E:192 ||| NN
.  ||| S:192 E:194 ||| .
Very  ||| S:194 E:199 ||| RB
few  ||| S:199 E:203 ||| JJ
new  ||| S:203 E:207 ||| JJ
drugs  ||| S:207 E:213 ||| NNS
active  ||| S:213 E:220 ||| JJ
against  ||| S:220 E:228 ||| IN
CPE  ||| S:228 E:232 ||| NNP
are  ||| S:232 E:236 ||| VBP
expected  ||| S:236 E:245 ||| VBN
to  ||| S:245 E:248 ||| TO
be  ||| S:248 E:251 ||| VB
clinically  ||| S:251 E:262 ||| RB
available ||| S:262 E:271 ||| JJ
.  ||| S:271 E:273 ||| .
Studies  ||| S:273 E:281 ||| NNS
summarized  ||| S:281 E:292 ||| VBD
in  ||| S:292 E:295 ||| IN
this  ||| S:295 E:300 ||| DT
review  ||| S:300 E:307 ||| NN
show  ||| S:307 E:312 ||| NN
that  ||| S:312 E:317 ||| IN
there  ||| S:317 E:323 ||| EX
is  ||| S:323 E:326 ||| VBZ
yet  ||| S:326 E:330 ||| RB
room  ||| S:330 E:335 ||| NN
to  ||| S:335 E:338 ||| TO
improve  ||| S:338 E:346 ||| VB
our  ||| S:346 E:350 ||| PRP$
therapeutic  ||| S:350 E:362 ||| JJ
approaches ||| S:362 E:372 ||| NNS
,  ||| S:372 E:374 ||| ,
in  ||| S:374 E:377 ||| IN
the  ||| S:377 E:381 ||| DT
treatment  ||| S:381 E:391 ||| NN
of  ||| S:391 E:394 ||| IN
infections  ||| S:394 E:405 ||| JJ
due  ||| S:405 E:409 ||| JJ
to  ||| S:409 E:412 ||| TO
CPE ||| S:412 E:415 ||| NNP
.  ||| S:415 E:417 ||| .
